Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC

Study ID: NCT04093167
Start Date: 2020-05-26
End Date: 2027-07-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

230

Intervention / Treatment

Pembrolizumab

Sponsor

Canadian Cancer Trials Group

Source: clinicaltrials.gov

Share:
Add to list

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

Study ID: NCT06295367
Start Date: 2024-02-29
End Date: 2027-12-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

760

Intervention / Treatment

Best Practice

Financial Navigation

Interview

Survey Administration

Sponsor

ECOG-ACRIN Cancer Research Group

Source: clinicaltrials.gov

Share:
Add to list

Comprehensive Connected Cancer Care (C4): Intervention Evaluation

Study ID: NCT06326567
Start Date: 2024-02-01
End Date: 2027-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment

C4 program

Sponsor

Timothy Mullett

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Study ID: NCT06824467
Start Date: 2025-04-09
End Date: 2032-10-15
Study Type

Interventional

Study Phase

Phase3

No. of Participants

770

Intervention / Treatment

Sacituzumab tirumotecan

Infatuating

H1 receptor antagonist

H2 receptor antagonist

Acetaminophen (or equivalent)

Dexamethasone (or equivalent)

Steroid mouthwash (dexamethasone or equivalent)

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list

CD4CAR for CD4+ Leukemia and Lymphoma

Study ID: NCT03829540
Start Date: 2020-07-09
End Date: 2040-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

20

Intervention / Treatment

CD4CAR

Sponsor

Huda Salman

Source: clinicaltrials.gov

Share:
Add to list

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

Study ID: NCT02333604
Start Date: 2013-03
End Date: 2035-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

15000

Intervention / Treatment
Sponsor

Cancer Support Community, Research and Training Institute, Philadelphia

Source: clinicaltrials.gov

Share:
Add to list

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Study ID: NCT05727904
Start Date: 2023-03-30
End Date: 2030-03-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

670

Intervention / Treatment

Lifileucel plus Pembrolizumab

Pembrolizumab with Optional Crossover Period

Sponsor

Iovance Biotherapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer

Study ID: NCT05665504
Start Date: 2023-01-11
End Date: 2028-02
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

250

Intervention / Treatment

DetermaRX

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Source: clinicaltrials.gov

Share:
Add to list

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Study ID: NCT02021604
Start Date: 2013-10-09
End Date: 2028-06
Study Type

Interventional

Study Phase

Phase1

No. of Participants

250

Intervention / Treatment

Fluorodopa F 18

Sponsor

Cook Children's Health Care System

Source: clinicaltrials.gov

Share:
Add to list

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Study ID: NCT05922904
Start Date: 2023-12-14
End Date: 2027-10-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

25

Intervention / Treatment

Bentuximab Vidotin

Doxorubicin Hydrochloride

Pembrolizumab

Dacarbazine

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list